1. Home >
  2. M&A >
  3. Consolidation >
  4. United States >
  5. California >
  6. The BroadOak Fund Acquires Precision Cell Systems

Consolidation • Life Science

The BroadOak Fund Acquires Precision Cell Systems

On September 17, 2025, growth capital firm The BroadOak Fund acquired life science company Precision Cell Systems

Acquisition Context
  • This is The BroadOak Fund’s 21st transaction in the Life Science sector.
  • This is The BroadOak Fund’s 24th transaction in the United States.
  • This is The BroadOak Fund’s 10th transaction in California.

Explore All 295 Consolidation Life Science Deals - Search the Database Free


M&A Deal Summary
Date September 17, 2025
Target Precision Cell Systems
Sector Life Science
Buyer(s) The BroadOak Fund
Deal Type Consolidation

Target Company

Precision Cell Systems

Livermore, California, United States
Precision Cell Systems is a cell analysis tools company that consolidates groundbreaking technologies to create sustainable businesses with clear paths to profitability. By integrating complementary workflow technologies and streamlining operations, PCS provides the infrastructure necessary to transform promising innovations into reliable, market-ready solutions for researchers and drug developers. Precision Cell Systems was formed in 2025 and is headquartered in Livermore, California.
Explore More Deals

Browse All 215,156 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Buyer Overview 1

Buyer

The BroadOak Fund

Investor Investor Investor Investor Investor

Category Growth Capital Firm
Size Small
Type Sector Focused
DESCRIPTION

The BroadOak Fund is the investment affiliate of life science focused investment bank BroadOak Capital Partners. The BroadOak Fund provides growth capital to life sciences tools and service providers that have achieved a level of commercial success. The BroadOak Fund is based in Bethesda, Maryland.

Deal Context for Buyer #
Overall 26 of 26
Sector: Life Science 21 of 21
Type: Consolidation 1 of 1
State: California 10 of 10
Country: United States 24 of 24
Year: 2025 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2025-09-17 S2 Genomics

Livermore, California, United States

S2 Genomics develops automated processing of raw tissues into single cells or nuclei for genomics and cell biology studies. S2 Genomics is based in Livermore, California.

Sell -

Explore Related M&A Activity

Life Science M&A - Consolidation M&A Deals - California M&A - United States M&A - 2025 M&A

Mergr

Solution for

Product

Company

Legal